维普期刊资源整合服务平台（V6.5）

55篇 您的检索式：作者名="Ryan CW"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Diethylstilbestrol and docetaxel:a PhaseⅡ study of tubulin active agents in patents with metastatic,androgen-independent prostate cancer显示文摘	Montgomery RB Nelson PS lin D Ryan CW Garzotto M Beer TM	2007	Cancer2007，110，5：	1
2	Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 (abst) 显示文摘	Ryan CW Goldman BH Lara PN	2006	Proc Am Soc Clin Oncol2006，24，：	1
3	The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tis- sue sarcoma 显示文摘	Ryan CW Desai J	2013	Am Soc Clin Oncol Edue Book2013，2013，：	1
4	Double-blinded randomized study of high-dose calcitfiol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators显示文摘	Beer TM Ryan CW Venner PM	2007	J Clin Oncol2007，25，6：	1
5	Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group 显示文摘	Ryan CW Goldman BH Lara PN Jr	2007	J Clin Onco12007，25，22：	1
6	Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era显示文摘	Wu PC Langerman A Ryan CW	2003	Surg2003，134，4：	1
7	Vaccines for the prevention of cardiovascular disease 显示文摘	Ryan US Rittershaus CW	2006	Vasc Pharmacol2006，45，5：	1
8	Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase Ⅱ study of the Southwest Oncology Group 显示文摘	Ryan CW Goldman BH Lara PNJr	2007	J Clin Oncol2007，25，22：	1
9	Double-blinded randomized study of high-dose calcitriol plus docetaxel com-pared with placebo plus dovetaxel in androgen-independent prostate cancer:a report from the ASCENT I nvestigators显示文摘	Beer TM Ryan CW Venner PM		0，，06：	1
10	Correction of sickle cell disease by homologous recombination in embryonic stem cells 显示文摘	Wu LC Sun CW Ryan TM	2006	Blood2006，108，4：	1
11	A review of chemotherapy trials for malignant mesothelioma显示文摘	Ryan CW Hemclin J Vogelzang NJ	1998	Chest1998，，：	1
12	Sorafenib plus interferon-α2b(IFN) as first-line therapy for advanced renal cell carcinoma (RCC) : SWOG 0412 显示文摘	Ryan CW Goldman BH Lara PN	2006	J Clin Oncol2006，24，18：	1
13	Sorafenib with inter- feron alfa-2b as first-line treatment of advanced renal carcinoma: a phase 11 stud~' of the Southwest Oncology Group 显示文摘	Ryan CW Goldman BH Lara PN Jr	2007	J Clin Oncol2007，25，22：	1
14	Sorafenib with interferonalfa -2b as first - line teratment of advanced renal carcinoma aphase II study of the Southwest Onclogy Group 显示文摘	Ryan CW Goldman BH Lara PJ	2007	J Clin Oncol2007，25，22：	1
15	Surgical treatment of gastrointestinal stromal tumors in the imatinib( STI-571 ) era显示文摘	Wu PC Langerman A Ryan CW	2003	Surgery2003，134，4：	1
16	Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy显示文摘	Israeli RS Ryan CW Jung LL	2008	J Urol2008，179，：	1
17	Surgical treatment of gastrointestinal stromaltumors in the imatinib(sTI-571) era显示文摘	Wu PC Langemlan A Ryan CW	2003	Surgery2003，134，4：	1
18	Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy显示文摘	Huo D Stallings JW	2007	Urology2007，70，：	1
19	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer:a report from the ASCENT Investigators显示文摘	Beer TM Ryan CW Venner PM	2007	J Clin Oncol2007，25，6：	1
20	Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid显示文摘	RYAN CW HUO D BYLOW K	2007	BJUInt2007，100，1：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示